Kymera Therapeutics KYMR
United StatesHealthcare · BiotechnologyUSD
139.32 USD (+28.6%)
22 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Kymera Therapeutics is a clinical-stage biopharmaceutical company developing protein degradation medicines (PROTAC technology) to treat immunological diseases and cancer.
Key points
from its scores- ✓Strong growth10.0
- ✓Good share-price trend9.8
- ✕Little competitive advantage0.7
- ✕Demanding valuation0.8
- ✕Little or no dividend1.5
AI analysis
bottom line, main risk, context and newsHold only for investors with high risk tolerance and a long-term horizon, given the pre-revenue profile and high volatility (beta 2.14).
Kymera is a clinical-stage biotech with spectacular revenue growth (466.40%) but not yet profitable (operating margin -116.32%), explaining its low quality (0.65) and valuation (0.8) scores. Its balance sheet is solid (liquidity 10.34, net debt/EBITDA 1.80) and strong momentum (9.8) reflects market confidence in its technology platform.
The main risk is the failure of its clinical candidates in advanced stages, which would leave the company without revenue and with a valuation based solely on future expectations.
Context and risks
No relevant recent news. The macro context (rates, dollar, oil) does not materially affect a development-stage biotech with net cash and no revenue dependent on commodities or significant external financing.
Is Kymera Therapeutics stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 2,411% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 5.9 | 4.1 | +45% |
| Price / sales | 85.8 | 3.4 | +2,411% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 139.32 USD, +28.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 0.7 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −21.3
- EV / EBITDA
- −24.7
- Price / book
- 5.9
- Price / sales
- 85.8
- Market cap
- 9.0B USD
- Enterprise value
- 8.4B USD
Profitability
- ROE
- −24.2%
- ROA
- −15.6%
- ROIC (approx.)
- −7.7%
- Gross margin
- −257.7%
- Operating margin
- −116.3%
- Net margin
- −285.3%
- Free cash flow
- −144.1M USD
- FCF yield
- −1.6%
Solvency
- Total debt
- 78.6M USD
- Net debt
- −612.4M USD
- Cash
- 691.0M USD
- EBITDA
- −339.9M USD
- Net debt / EBITDA
- 1.80
- Debt / equity
- 5.21
- Current ratio
- 10.34
- Quick ratio
- 9.97
Growth
- Revenue growth
- +466.4%
- EPS (TTM)
- −3.25 USD
- EPS (forward)
- −5.09 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.98
- Analyst consensus
- Strong buy (22)
- Target price
- 139.32 USD
- 52-week range
- 55.26 – 130.05
Recent news
All KYMR news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Kymera Therapeutics
Is Kymera Therapeutics stock cheap or expensive?
On Price / sales, it trades 2,411% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 139.32 USD, +28.6% versus the price. This is not investment advice.
What score does Kymera Therapeutics get on MeridIAn Screener?
It scores 3.5 out of 10, rank 2,034 of 2,130 (better than 4% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Quality / Moat (0.7). Analysis of 08/10/2026.
How much is Kymera Therapeutics worth on the stock market?
Its market capitalisation is 9.0B USD and its enterprise value, debt included, is 8.4B USD.
How much debt does Kymera Therapeutics have?
It has more cash than debt: net cash of 612.4M USD.
Does Kymera Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Kymera Therapeutics stock performed over the last year?
It has risen 89.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 55.26 and 130.05 USD. Past performance does not guarantee future results.
What do analysts think of Kymera Therapeutics?
22 analysts cover it; their average recommendation is “Strong buy” and their average target is 139.32 USD (+28.6% versus the price). It is an estimate, not market data.